Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd., a leading player in the pharmaceutical and healthcare industry, is headquartered in Beijing, China. Founded in 1998, the company has established itself as a pivotal force in the distribution of pharmaceuticals, medical devices, and healthcare services across various regions, including Asia, Europe, and Africa. With a diverse portfolio that includes vaccines, blood products, and diagnostic reagents, Sinopharm is renowned for its commitment to innovation and quality. The company has achieved significant milestones, such as being a key supplier of COVID-19 vaccines, which has bolstered its market position globally. Sinopharm's extensive distribution network and strong partnerships further enhance its reputation as a trusted provider in the healthcare sector, making it a cornerstone of China's pharmaceutical landscape.
DitchCarbon Score
How does Sinopharm Group Co. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinopharm Group Co. Ltd.'s score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinopharm Group Co. Ltd.'s reported carbon emissions
In 2021, Sinopharm Group Co. Ltd. reported total carbon emissions of approximately 215,691,450 kg CO2e. This figure includes about 51,430,120 kg CO2e from Scope 1 emissions and approximately 164,261,330 kg CO2e from Scope 2 emissions. The company has shown a slight increase in emissions from 2020, where total emissions were about 208,213,060 kg CO2e, with Scope 1 at approximately 52,946,470 kg CO2e and Scope 2 at around 155,266,590 kg CO2e. Sinopharm has set ambitious climate commitments, aiming for net zero emissions by 2030 for both Scope 1 and Scope 2 emissions. This commitment was established in 2023, indicating a proactive approach to reducing their carbon footprint in the near term. The company does not currently disclose Scope 3 emissions data, which encompasses indirect emissions in the value chain. However, their focus on achieving net zero for direct and indirect emissions reflects a growing trend in the pharmaceutical industry towards sustainability and climate responsibility. Overall, Sinopharm Group Co. Ltd. is actively working towards significant emissions reductions, aligning with global climate goals and demonstrating a commitment to environmental stewardship.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinopharm Group Co. Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
